Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoTherapy ScienceTSE:4564 -4.76%50 Net Current Asset Value is 円5.45 as of Mar. 2026, which is 100% below its 10-year median of 5.99. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円16.92 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, OncoTherapy Science ranks better than 56.96% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
OncoTherapy Science's net current asset value per share for the quarter that ended in Mar. 2026 was 円5.45.
The historical rank and industry rank for OncoTherapy Science's Net Current Asset Value or its related term are showing as below:
TSE:4564'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.42 Med: 5.99 Max: 15
Current: 3.67
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of OncoTherapy Science was 15.00. The lowest was 2.42. And the median was 5.99.
TSE:4564's Price-to-Net-Current-Asset-Value is ranked better than 56.96% of 941
companies
in the Biotechnology industry
Industry Median: 4.81
vs TSE:4564: 3.67
OncoTherapy Science (TSE:4564) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
OncoTherapy Science Net Current Asset Value Related Terms
OncoTherapy Science Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, OncoTherapy Science's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of 円5.45 mean?
OncoTherapy Science (TSE:4564) has a Net Current Asset Value of 円5.45 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on OncoTherapy Science and its competitors. This is near median its historical median of 5.99. Over the past decade, OncoTherapy Science's Net Current Asset Value has ranged from 2.42 to 15.00. According to the industry distribution chart, OncoTherapy Science ranks #405 out of 941 companies in the Biotechnology industry, placing it in the top 43%.
Is OncoTherapy Science's Net Current Asset Value too high?
OncoTherapy Science's current Net Current Asset Value of 円5.45 is near median its 10-year median of 5.99. Over the past 10 years, this metric has ranged from a low of 2.42 to a high of 15.00. Based on the distribution chart, OncoTherapy Science ranks #405 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #405 out of 941 companies for Net Current Asset Value. This puts OncoTherapy Science in the upper half of its industry. The industry median Net Current Asset Value is 4.81. Historically, OncoTherapy Science's own Net Current Asset Value has ranged from 2.42 to 15.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.81, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on OncoTherapy Science and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current Net Current Asset Value is 円5.45, which is near median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円16.92, compared to a current price of 円20.00 — trading 18.2% above its estimated fair value. The current Net Current Asset Value is 円5.45, which is near median its 10-year median of 5.99. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Net Current Asset Value is 円5.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円20.00 is trading 18.2% above its estimated GF Value™ of 円16.92.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Net Current Asset Value: 円5.45 (near median its 10-year median of 5.99)
GF Value™: 円16.92 vs. price of 円20.00 (18.2% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
